Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Articles

PI3K Inhibitors for PIK3CA-Mutated HR+ MBC

November 15th 2021

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

Targeting the PI3K Pathway in HR+/HER2- MBC

November 15th 2021

The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.

CDK4/6 Treatment Selection for HR+/HER2- MBC

November 8th 2021

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

Comparison of CDK4/6 Therapies for HR+/HER2- MBC

November 8th 2021

Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities

November 1st 2021

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

HR+/HER2- MBC: CDK4/6 Inhibitors + ET as Frontline Therapy

November 1st 2021

Dr. Sarah Sammons highlights various first-line treatment approaches that combine CDK4/6 inhibitors with endocrine therapy as treatment for HR+/HER2- metastatic breast cancer.

MONALEESA Data in HR+/HER2- MBC: Sequencing Therapy

October 25th 2021

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.

Ribociclib + ET for HR+/HER2- MBC: QoL and OS Data

October 25th 2021

Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.

HR+/HER2- MBC: Updated OS Data From MONALEESA-2

October 18th 2021

Reactions to new overall survival results from the MONALEESA-2 study in patients with HR+/HER2- advanced breast cancer in the first-line setting.

Frontline Treatment Approaches for HR+/HER2- MBC

October 18th 2021

A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.

HR+ MBC: Prognostic Factors and Treatment Planning

October 11th 2021

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Identifying PIK3CA Mutations in HR+ HER2- MBC

October 11th 2021

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.

Monitoring Patients for Interstitial Lung Disease

October 1st 2021

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

Identifying Risk Factors for Interstitial Lung Disease

October 1st 2021

A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.

Identifying ILD: Symptomology and Work-Up

September 24th 2021

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

An Overview of Interstitial Lung Disease

September 24th 2021

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Multidisciplinary Care in Breast Cancer: Take-Home Messages

September 22nd 2021

Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.

Practical Considerations for Identifying and Managing ILD in Breast Cancer

September 22nd 2021

Drawing from personal experience, experts provide practical advice on identifying and treating interstitial lung disease in patients with breast cancer during the era of COVID-19.

Optimal Management of ILD in Patients With Breast Cancer

September 15th 2021

Shared insight on the optimal management of patients who develop interstitial lung disease while receiving therapy for breast cancer.

Breast Cancer Management: Monitoring Patients for ILD

September 15th 2021

In light of breast cancer therapies with the potential to cause interstitial lung disease, experts consider important patient risk factors and best monitoring practices.